16:10 EST Halozyme sees FY24 royalty revenue $500M-$525M
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HALO:
- HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS
- Halozyme announces Takeda received EC approval for HYQVIA
- Halozyme announces approval for Vydura in Japan
- Halozyme price target lowered to $48 from $61 at H.C. Wainwright
- Halozyme: Takeda receives FDA approval of HYQVIA co-formulated with ENHANZE